TY - JOUR A1 - Bubna, Aditya T1 - Apremilast: A dermatologic perspective Y1 - 2016/7/1 JF - Indian Journal of Drugs in Dermatology JO - Indian J Drugs Dermatol SP - 75 EP - 82 VL - 2 IS - 2 UR - https://www.ijdd.in/article.asp?issn=2455-3972;year=2016;volume=2;issue=2;spage=75;epage=82;aulast=Bubna DO - 10.4103/2455-3972.196166 N2 - Apremilast is an oral phosphodiesterase 4 inhibitor, now approved by the Food and Drug Administration in the management of psoriatic arthropathy (PsA). As biologic therapy is associated with significant amounts of adverse effects, newer treatment options with an efficacious outcome, sans the toxicity, is something all clinicians would implement readily in their therapeutic regimens. Apremilast is one such drug which has shown promise in the management of psoriasis, PsA, and a few other dermatologic disorders. This review will throw light on the dermatologic perspective regarding apremilast. ER -